Drug-Eluting Balloon Angioplasty Versus Bypass Surgery as First-Line Strategies in Infrageniculate Arterial Disease for Critical Limb Ischemia in Type 2 Diabetic Pacients: a Randomised Controlled Clinical Trial
Primary Purpose
Critical Limb Ischemia
Status
Recruiting
Phase
Not Applicable
Locations
Lithuania
Study Type
Interventional
Intervention
Vein bypass surgery first strategy
Endovascular treatment first (drug coated balloon angioplasty) strategy
Sponsored by
About this trial
This is an interventional treatment trial for Critical Limb Ischemia
Eligibility Criteria
Inclusion Criteria:
- Patient with type 2 diabetes mellitus
- Severe limb ischemia (Rutherford class >=4) due to infrapopliteal, +/- popliteal disease [ a.tibialis anterior, tr.tibioperonealis, a.peronea, a.tibialis posterior, a.dorsalis pedis stenosis or occlusion (50%-100%; >40mm in length); leasion may involve a.poplitea P1-P3 segment; have adequate inflow and outflow to support infrapopliteal intervention (diagnostic imaging); suitable for both vein bypass and best endovascular treatment following; angiography diagnostic imaging and ultrasound examination of vein conduit.]
Exclusion Criteria:
- Requires primary limb amputation
- Acute limb ischemia
- Anticipated life expectancy of <2 years
- Unsuitable for either revascularisation strategy
- Severe concomitant disease (acute coronary ischemic event, brain ischemic event, cognitive disorder, active oncology process)
Sites / Locations
- Lithuanian University of Health SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Vein bypass surgery first strategy
Endovascular treatment first (drug coated balloon angioplasty) strategy
Arm Description
Outcomes
Primary Outcome Measures
Primary, primary-assisted and secondary patency
Clinical and ultrasound assesment
Secondary Outcome Measures
Ischemic symptoms
Fontaine classification: I asymptomatic; IIa mild claudication; IIb moderate-to-severe claudication; III rest pain; IV ulceration or gangrene.
Rutherford classification: 0 asymptomatic; 1 mild claudication; 2 moderate claudication; 3 severe claudication; 4 rest pain; 5 minor tissue loss; 6 severe tissue loss or gangrene.
Ankle-brachial index (ABI)
Ratio of the blood pressure at the ankle to the blood pressure in the upper arm. Norm 1.0-1.4
Toe-brachial index (TBI)
Ratio of the blood pressure of the great toe to the blood pressure in the upper arm. Norm 1.0-1.4
Transcutaneous oxygen tension (TcPO2)
A noninvasive test that directly measures the oxygen level of tissue beneath the skin. A TcPO2 greater than 55 mmHg is considered normal regardless of the site of measurement, whereas a value of 40 mmHg is the critical value below which wound healing is impaired and ischemia develops.
Healing of tissue loss (ulcers, gangrene)
Clinical examination and photo documentation.
Re- and cross-over intervention rates
Major and minor amputation rates
In-hospital morbidity/mortality and overall survival
Relief of pain: Visual analog scale (VAS)
The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain).
Quality of life: EQ-5D-5L questionaire
Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension.
Diabetic neuropathy dinamics: clinical examination of foot sensation
Full hypoesthesia; Partial hypoesthesia; No changes; + Assymetry.
Diabetic neuropathy dinamics: neurometer
Perception threshold measurement. Neurometer® determines three sub-types of nerve fiber by producing transcutaneous electrical stimuli at frequencies of 2000, 250 and 5 Hz.
Diabetic neuropathy dinamics: electroneuromiography
Diagnostic procedure that evaluates the health condition of muscles and the nerve cells that control them. A nerve conduction velocity between 50 and 60 meters per second is generally considered in the normal range.
Full Information
NCT ID
NCT04760119
First Posted
January 22, 2021
Last Updated
February 15, 2021
Sponsor
Lithuanian University of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04760119
Brief Title
Drug-Eluting Balloon Angioplasty Versus Bypass Surgery as First-Line Strategies in Infrageniculate Arterial Disease for Critical Limb Ischemia in Type 2 Diabetic Pacients: a Randomised Controlled Clinical Trial
Official Title
Drug-Eluting Balloon Angioplasty Versus Bypass Surgery as First-Line Strategies in Infrageniculate Arterial Disease for Critical Limb Ischemia in Type 2 Diabetic Pacients: a Randomised Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2020 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lithuanian University of Health Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to evaluate the outcomes of drug-eluting balloon angioplasty and vein bypass surgery in diabetic patients with critical limb ischemia due to infrapopliteal arterial disease.
Detailed Description
Objective: To consider the clinical outcomes of drug-coated ballon angioplasty and vein bypass surgery in terms of amputation-free survival, overall survival, relief of symptoms, quality of life and to determine if limb revascularization contributes to diabetic peripheral neuropathy (DPN).
All patients with type 2 diabetes mellitus and severe limb ischemia reffered to multidisciplinary diabetic foot team or endocrinology or vascular units can be considered.
To be eligible for randomization, peripheral arterial occlusive disease must be located infra-popliteally; patients must have adequate inflow and outflow to support infrapopliteal interventions; have a good superficial vein for bypass surgery. If the patient is suitable for both treatment arms, they will be invited to enter the trial.
If patient is suitable for both revascularization techniques randomization will be performed after diagnostic angiogram submission
Patient will be randomised to one of the following groups:
A. Vein bypass surgery first strategy B. Endovascular treatment first (drug coated balloon angioplasty) strategy
Outcomes will be recorded at 1, 3, 6, 9, 12, 18, 24 month after revascularisation procedure. Information collected will include further interventions (vascular, non-vascular), hospitalisations (for whatever reason), other health problems, clinical and haemodinamic status of limbs, funcional status, quality of life, neuropathy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Limb Ischemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The treatment will consist of two treatment modalities: 1) Vein bypass surgery first strategy; 2) Endovascular treatment first (drug coated balloon angioplasty) strategy
Masking
None (Open Label)
Masking Description
Blinding is not possible due to the completely different natures of the treatments allocated.
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vein bypass surgery first strategy
Arm Type
Active Comparator
Arm Title
Endovascular treatment first (drug coated balloon angioplasty) strategy
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Vein bypass surgery first strategy
Intervention Description
Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
Intervention Type
Procedure
Intervention Name(s)
Endovascular treatment first (drug coated balloon angioplasty) strategy
Intervention Description
Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
Primary Outcome Measure Information:
Title
Primary, primary-assisted and secondary patency
Description
Clinical and ultrasound assesment
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Ischemic symptoms
Description
Fontaine classification: I asymptomatic; IIa mild claudication; IIb moderate-to-severe claudication; III rest pain; IV ulceration or gangrene.
Rutherford classification: 0 asymptomatic; 1 mild claudication; 2 moderate claudication; 3 severe claudication; 4 rest pain; 5 minor tissue loss; 6 severe tissue loss or gangrene.
Time Frame
24 months
Title
Ankle-brachial index (ABI)
Description
Ratio of the blood pressure at the ankle to the blood pressure in the upper arm. Norm 1.0-1.4
Time Frame
24 months
Title
Toe-brachial index (TBI)
Description
Ratio of the blood pressure of the great toe to the blood pressure in the upper arm. Norm 1.0-1.4
Time Frame
24 months
Title
Transcutaneous oxygen tension (TcPO2)
Description
A noninvasive test that directly measures the oxygen level of tissue beneath the skin. A TcPO2 greater than 55 mmHg is considered normal regardless of the site of measurement, whereas a value of 40 mmHg is the critical value below which wound healing is impaired and ischemia develops.
Time Frame
24 months
Title
Healing of tissue loss (ulcers, gangrene)
Description
Clinical examination and photo documentation.
Time Frame
24 months
Title
Re- and cross-over intervention rates
Time Frame
24 months
Title
Major and minor amputation rates
Time Frame
24 months
Title
In-hospital morbidity/mortality and overall survival
Time Frame
24 months
Title
Relief of pain: Visual analog scale (VAS)
Description
The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain).
Time Frame
24 months
Title
Quality of life: EQ-5D-5L questionaire
Description
Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension.
Time Frame
24 months
Title
Diabetic neuropathy dinamics: clinical examination of foot sensation
Description
Full hypoesthesia; Partial hypoesthesia; No changes; + Assymetry.
Time Frame
24 months
Title
Diabetic neuropathy dinamics: neurometer
Description
Perception threshold measurement. Neurometer® determines three sub-types of nerve fiber by producing transcutaneous electrical stimuli at frequencies of 2000, 250 and 5 Hz.
Time Frame
24 months
Title
Diabetic neuropathy dinamics: electroneuromiography
Description
Diagnostic procedure that evaluates the health condition of muscles and the nerve cells that control them. A nerve conduction velocity between 50 and 60 meters per second is generally considered in the normal range.
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with type 2 diabetes mellitus
Severe limb ischemia (Rutherford class >=4) due to infrapopliteal, +/- popliteal disease [ a.tibialis anterior, tr.tibioperonealis, a.peronea, a.tibialis posterior, a.dorsalis pedis stenosis or occlusion (50%-100%; >40mm in length); leasion may involve a.poplitea P1-P3 segment; have adequate inflow and outflow to support infrapopliteal intervention (diagnostic imaging); suitable for both vein bypass and best endovascular treatment following; angiography diagnostic imaging and ultrasound examination of vein conduit.]
Exclusion Criteria:
Requires primary limb amputation
Acute limb ischemia
Anticipated life expectancy of <2 years
Unsuitable for either revascularisation strategy
Severe concomitant disease (acute coronary ischemic event, brain ischemic event, cognitive disorder, active oncology process)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Viktoras Šliaužys, M.D.
Phone
+37064297161
Email
viktoras.sliauzys@lsmuni.lt
First Name & Middle Initial & Last Name or Official Title & Degree
Džilda Veličkienė, Prof
Email
dzilda.velickiene@lsmuni.lt
Facility Information:
Facility Name
Lithuanian University of Health Sciences
City
Kaunas
State/Province
LT
ZIP/Postal Code
50161
Country
Lithuania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vaiva Lesauskaitė, Prof
Phone
(8 37) 32 72 06
Email
vaiva.lesauskaite@lsmuni.lt
First Name & Middle Initial & Last Name & Degree
Viktoras Šliaužys
First Name & Middle Initial & Last Name & Degree
Džilda Veličkienė, Prof
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Drug-Eluting Balloon Angioplasty Versus Bypass Surgery as First-Line Strategies in Infrageniculate Arterial Disease for Critical Limb Ischemia in Type 2 Diabetic Pacients: a Randomised Controlled Clinical Trial
We'll reach out to this number within 24 hrs